Association of Tumor Mutational Burden and Microsatellite Instability With Response and Outcomes in Patients With Urothelial Carcinoma Treated With Immune Checkpoint Inhibitor

By sjmartinez • September 8, 2024

Bakaloudi DR, Talukder R, Makrakis D, Diamantopoulos L, Enright T, Leary JB, Patgunarajah U, Thomas VM, Swami U, Agarwal N, Jindal T, Koshkin VS, Brown JR, Barata P, Murgić J, Miletić M, Johnson J, Zakharia Y, Hui G, Drakaki A, Duran I, Buznego LA, Barrera RM, Castañeda DM, Rey-Cárdenas M, Castellano D, Nguyen CB, Park JJ, Alva A, McKay RR, Stewart TF, Epstein IB, Bellmunt J, Wright JL, Gupta S, Grivas P, Khaki AR. Association of Tumor Mutational Burden and Microsatellite Instability With Response and Outcomes in Patients With Urothelial Carcinoma Treated With Immune Checkpoint Inhibitor. Clin Genitourin Cancer. 2024 Aug 12;22(6):102198. doi: 10.1016/j.clgc.2024.102198. Epub ahead of print. PMID: 39241315.

Tags: biomarkers, Bladder cancer, Fellow, Genomics, Hematology/Oncology, immunotherapy, Publications, urothelial carcinoma

Neoadjuvant Antiandrogen Therapy With or Without MEK or SRC Inhibition for Unfavorable-risk Prostate Cancer: A Phase 2 Randomized Clinical Trial

Agrawal R, Weiner AB, Livingstone J, Pooli A, Huang RR, Ye H, Sisk A, Elashoff DA, Boutros PC, Rettig MB, Reiter RE. Neoadjuvant Antiandrogen Therapy[...]

Safety and Clinical Outcomes of Pembrolizumab Standard-Interval Dosing Versus Extended-Interval Dosing in Patients with Breast Cancer

LeVee A, Kordic A, Ruel N, Mortimer J, Kang I, McArthur H, Lechner MG, Tsai K. Safety and Clinical Outcomes of Pembrolizumab Standard-Interval Dosing Versus[...]

Differences in treatment decision-making for non-small cell lung cancer among patients and physicians, by race and ethnicity

Dwyer Orr L, Vadagam P, Vanderpoel J, Patel MI, Basu Roy U, Ledezma B, Yung M, Deering KL, Kulbokas V, Feldman J, Gray JE. Differences[...]